Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198264 | 1.00 | LMNA (0.59) | LMNAMAPK1UGT2B7SLC6A2SLC6A4 | |
| SCHEMBL29785786 | 1.00 | LMNA (0.59) | LMNAMAPK1UGT2B7SLC6A2SLC6A4 | |
| SCHEMBL2683267 | 1.00 | LMNA (0.59) | LMNAMAPK1UGT2B7SLC6A2SLC6A4 | |
| SCHEMBL28555283 | 0.83 | CES2 (0.63) | LMNAUGT2B7SLC6A2SLC6A4SLC6A3 | |
| Mandelic Acid SCHEMBL29547062 | 0.83 | LMNA (0.86) | LMNAMAPK1CYP2D6KMT2ABLM | |
| SCHEMBL19042004 | 0.82 | UGT2B7 (0.60) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7150615 | 0.82 | SRC (0.58) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL3579124 | 0.82 | UGT2B7 (0.53) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 | |
| Mandelic Acid SCHEMBL6425366 | 0.80 | SNCA (0.55) | LMNAMAPK1TSHR | |
| SCHEMBL6839913 | 0.80 | UGT2B7 (0.52) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| EP-3196185-B1 | ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND | ZHEJIANG JIUZHOU PHARMA SCIENCE & TECH CO LTD (CN) | 2019-06-12 | — | — | EP | disclosed |
| EP-3196185-B1 | ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND | ZHEJIANG JIUZHOU PHARMA SCIENCE & TECH CO LTD (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-10112884-B2 | Asymmetrical hydrogenation reaction of ketonic acid compound | ZHEJIANG JIUZHOU PHARMA SCIENCE & TECH CO LTD (CN) | 2018-10-30 | — | — | US | disclosed |
| US-20170260119-A1 | Asymmetrical hydrogenation reaction of ketonic acid compound | ZHEJIANG JIUZHOU PHARMA SCIENCE&TECHNOLOGY CO LTD (CN) | 2017-09-14 | — | — | US | disclosed |
| US-20170260119-A1 | Asymmetrical hydrogenation reaction of ketonic acid compound | ZHEJIANG JIUZHOU PHARMA SCIENCE&TECHNOLOGY CO LTD (CN) | 2017-09-14 | — | — | US | disclosed |
| US-20170260119-A1 | Asymmetrical hydrogenation reaction of ketonic acid compound | ZHEJIANG JIUZHOU PHARMA SCIENCE&TECHNOLOGY CO LTD (CN) | 2017-09-14 | — | — | US | disclosed |
| EP-3196185-A1 | ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND | Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-3196185-A1 | ASYMMETRICAL HYDROGENATION REACTION OF KETONIC ACID COMPOUND | Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| EP-0915080-B1 | Process for preparing optically active amines and optically active carboxylic acids, and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6342636-B1 | REACTION OF ARYLALKYLAMINE WITH NAPHTHYLGLYCOLIC ACID AND DECOMPOSITION A DIASTEROMER SALT TO OBTAIN AN ENANTIOMORPH | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-01-29 | — | — | US | disclosed |
| US-6337343-B1 | TREATMENT OF THROMBOSIS WITH ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| EP-0915080-A1 | Process for preparing optically active amines and optically active carboxylic acids, and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1999-05-12 | — | — | EP | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260119-A1 | Asymmetrical hydrogenation reaction of ketonic acid compound | KHK, PKLR, BCKDK | LMNA 3213/4885MAPK1 1240/4885UGT2B7 2143/4885 |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | LMNA 1127/4885MAPK1 475/4885UGT2B7 2702/4885 |
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | LMNA 3361/4885MAPK1 1223/4885UGT2B7 2662/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | LMNA 219/4885MAPK1 1200/4885UGT2B7 777/4885 |
| US-10112884-B2 | Asymmetrical hydrogenation reaction of ketonic acid compound | KHK, PKLR, BCKDK | LMNA 3213/4885MAPK1 1240/4885UGT2B7 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.